Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)

This study will assess the safety and effectiveness of a combination of BL-8040 and

atezolizumab to find out what is the Safety, Tolerability and Efficacy of this treatment

combination for maintenance treatment in subjects with acute myeloid leukemia.

This is a single arm, open label, Phase Ib/II study in which eligible subjects will

receive maintenance treatment consisting of intravenous (IV) infusion of Atezolizumab on

Day 2 of each 21-day cycle and subcutaneous (SC) injections of BL-8040 on Days 1, 2 and 3

of each 21-day cycle. Cycles will be repeated for up to 2 years (a maximum of 34

treatment cycles), until early discontinuation for any reason or until disease relapse,

whichever comes first.

Approximately 60 patients will take part at multiple centers worldwide.

The duration of the treatment period of the study will be up to 2 years and will be

followed by one year safety follow up. The study will consist of:

- a screening period of 21 days to allow your doctor to assess your suitability for

enrollment into the study

- a treatment period of combination regimen of 21 day cycles for up to 2 years

- a follow-up period of up to 30 days after completion of combined treatment with

BL-8040 + Atezolizumab

- an additional follow up period for up to one year after the completion of the

treatment